Ronald Berenson

Fe3 Medical, Inc. develops a transdermal therapy for iron deficiency anemia. It offers a disposable transdermal patch that delivers the amount of iron needed directly through the skin, bypassing the GI tract and eliminating undesirable side effects. The company was founded by Mir A. Imran in 2008 and is headquartered in San Antonio, TX.

Fe3 Medical, Inc. develops a transdermal therapy for iron deficiency anemia. It offers a disposable transdermal patch that delivers the amount of iron needed directly through the skin, bypassing the GI tract and eliminating undesirable side effects. The company was founded by Mir A. Imran in 2008 and is headquartered in San Antonio, TX.

KitoTech Medical, Inc. operates as a medical device company which develops medical products based on its proprietary micro staple technology platform. It specializes in wound closure, patient care, emergency laceration, surgery, skin closure device, and biotechnology. The company was founded by Ronald J. Berenson and Marco Rolandi in 2013 and is headquartered in Seattle, WA.

Fe3 Medical, Inc. develops a transdermal therapy for iron deficiency anemia. It offers a disposable transdermal patch that delivers the amount of iron needed directly through the skin, bypassing the GI tract and eliminating undesirable side effects. The company was founded by Mir A. Imran in 2008 and is headquartered in San Antonio, TX.

Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars.

Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars.

Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars.

Fe3 Medical, Inc. develops a transdermal therapy for iron deficiency anemia. It offers a disposable transdermal patch that delivers the amount of iron needed directly through the skin, bypassing the GI tract and eliminating undesirable side effects. The company was founded by Mir A. Imran in 2008 and is headquartered in San Antonio, TX.

Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars.

Fe3 Medical, Inc. develops a transdermal therapy for iron deficiency anemia. It offers a disposable transdermal patch that delivers the amount of iron needed directly through the skin, bypassing the GI tract and eliminating undesirable side effects. The company was founded by Mir A. Imran in 2008 and is headquartered in San Antonio, TX.

Fe3 Medical, Inc. develops a transdermal therapy for iron deficiency anemia. It offers a disposable transdermal patch that delivers the amount of iron needed directly through the skin, bypassing the GI tract and eliminating undesirable side effects. The company was founded by Mir A. Imran in 2008 and is headquartered in San Antonio, TX.

Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars.

KitoTech Medical, Inc. operates as a medical device company which develops medical products based on its proprietary micro staple technology platform. It specializes in wound closure, patient care, emergency laceration, surgery, skin closure device, and biotechnology. The company was founded by Ronald J. Berenson and Marco Rolandi in 2013 and is headquartered in Seattle, WA.